These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Lucas DM; Edwards RB; Lozanski G; West DA; Shin JD; Vargo MA; Davis ME; Rozewski DM; Johnson AJ; Su BN; Goettl VM; Heerema NA; Lin TS; Lehman A; Zhang X; Jarjoura D; Newman DJ; Byrd JC; Kinghorn AD; Grever MR Blood; 2009 May; 113(19):4656-66. PubMed ID: 19190247 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog. De Rosa MF; Ackerley C; Wang B; Ito S; Clarke DM; Lingwood C J Biol Chem; 2008 Feb; 283(8):4501-11. PubMed ID: 18003606 [TBL] [Abstract][Full Text] [Related]
9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547 [TBL] [Abstract][Full Text] [Related]
10. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Zhao XQ; Xie JD; Chen XG; Sim HM; Zhang X; Liang YJ; Singh S; Talele TT; Sun Y; Ambudkar SV; Chen ZS; Fu LW Mol Pharmacol; 2012 Jul; 82(1):47-58. PubMed ID: 22491935 [TBL] [Abstract][Full Text] [Related]
11. Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells. Liu DL; Li YJ; Yao N; Xu J; Chen ZS; Yiu A; Zhang CX; Ye WC; Zhang DM Eur J Pharmacol; 2014 Jun; 733():34-44. PubMed ID: 24704556 [TBL] [Abstract][Full Text] [Related]
12. The natural compound silvestrol is a potent inhibitor of Ebola virus replication. Biedenkopf N; Lange-Grünweller K; Schulte FW; Weißer A; Müller C; Becker D; Becker S; Hartmann RK; Grünweller A Antiviral Res; 2017 Jan; 137():76-81. PubMed ID: 27864075 [TBL] [Abstract][Full Text] [Related]
13. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128 [TBL] [Abstract][Full Text] [Related]
14. Dose-dependent targeted suppression of P-glycoprotein expression and function in Caco-2 cells. Lee SD; Osei-Twum JA; Wasan KM Mol Pharm; 2013 Jun; 10(6):2323-30. PubMed ID: 23611024 [TBL] [Abstract][Full Text] [Related]
15. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors. Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE Oncologist; 2012; 17(4):512. PubMed ID: 22416063 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Duan Z; Brakora KA; Seiden MV Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144 [TBL] [Abstract][Full Text] [Related]
17. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Broxterman HJ; Sonneveld P; Feller N; Ossenkoppele GJ; Währer DC; Eekman CA; Schoester M; Lankelma J; Pinedo HM; Löwenberg B; Schuurhuis GJ Blood; 1996 Jun; 87(11):4809-16. PubMed ID: 8639853 [TBL] [Abstract][Full Text] [Related]
18. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif. Ye S; MacEachran DP; Hamilton JW; O'Toole GA; Stanton BA Am J Physiol Cell Physiol; 2008 Sep; 295(3):C807-18. PubMed ID: 18650266 [TBL] [Abstract][Full Text] [Related]
19. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein. Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542 [TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. Grundy M; Seedhouse C; Russell NH; Pallis M BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]